ABBV vs BIIB
By Alex · Tickerpine
AbbVie Inc. vs Biogen Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | ABBV | BIIB |
|---|---|---|
| Price | $266.28 | $228.69 |
| Market cap | $470.55B | $33.79B |
| P/E ratio | 75.0 | 40.7 |
| ROE | — | 4.58% |
| Profit margin | 9.80% | 8.32% |
| Revenue growth | 10.20% | 3.40% |
| Dividend yield | 2.62% | — |
| Beta | 0.28 | 0.17 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
ABBV vs BIIB in plain English
- ABBV is the bigger company — about 13.9× the market cap of BIIB.
- BIIB is cheaper on earnings (P/E 40.7 vs 75.0).
- ABBV is growing revenue faster (10% vs 3%).
- ABBV pays a dividend (2.62%) while the other effectively doesn't.
How would $1,000 have done in each?
ABBV return calculator
See what $1,000 in AbbVie Inc. would be worth today.
BIIB return calculator
See what $1,000 in Biogen Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.